BioCentury
ARTICLE | Finance

Manufacturing gateway

How Gates aims to lower cost of biologics by investing in Just Biotherapeutics

August 8, 2016 7:00 AM UTC

An $8 million equity investment in Just Biotherapeutics Inc. could give the Bill & Melinda Gates Foundation and its biotech partners access to a GMP facility designed to lower R&D and manufacturing costs for biologics.

The foundation led Just's $14 million A2 round on July 25, joined by existing investors Merck & Co. Inc. (NYSE:MRK), Lilly Asia Ventures and Arch Venture Partners. The money will be spent to complete a laboratory and pilot GMP manufacturing plant in Seattle by next year...